TG THERAPEUTICS, INC. - COMMON STOCK (TGTX)

Historical Holders from Q1 2014 to Q4 2025

Symbol
TGTX on Nasdaq
Type / Class
Equity / COMMON STOCK
Shares outstanding
158,835,667
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
99,009,650
Holdings value
$3,576,821,678
% of all portfolios
0%
Number of holders
349
Number of buys
149
Number of sells
180
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13% $739,151,518 20,134,882 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 10% $572,546,781 15,596,480 The Vanguard Group 31 Dec 2024
STATE STREET CORP 5.1% +8% $292,634,861 +$24,085,260 8,100,619 +9% STATE STREET CORPORATION 30 Sep 2025
As of 30 Sep 2025 TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 349 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 99,009,650 shares of 158,835,667 outstanding shares and own 62% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) own 49% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 21,300,425 -2.4% 0.01% $769,477,853
VANGUARD GROUP INC 9.8% 15,521,299 -1.8% 0.01% $560,706,927
STATE STREET CORP 5.1% 8,100,619 +6.3% 0.01% $292,634,862
Clearbridge Investments, LLC 2.9% 4,644,475 +52% 0.13% $167,781,649
Soleus Capital Management, L.P. 2.4% 3,844,731 +71% 7.4% $138,890,907
GEODE CAPITAL MANAGEMENT, LLC 2.2% 3,443,919 -1.3% 0.01% $125,039,327
Pictet Asset Management Holding SA 1% 1,609,551 -16% 0.06% $58,145,030
Hood River Capital Management LLC 0.98% 1,552,788 -0.94% 0.66% $56,094,467
GOLDMAN SACHS GROUP INC 0.96% 1,519,373 -3.2% 0.01% $54,887,349
NORTHERN TRUST CORP 0.95% 1,501,733 -2.2% 0.01% $54,250,106
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.82% 1,310,157 -0.48% 0.01% $47,329,445
MORGAN STANLEY 0.79% 1,247,801 -11% 0% $45,076,827
JANE STREET GROUP, LLC 0.71% 1,128,760 +60% 0.05% $40,776,455
Invesco Ltd. 0.69% 1,094,334 +13% 0.01% $39,532,816
Man Group plc 0.63% 1,008,462 +622% 0.07% $36,430,690
CITADEL ADVISORS LLC 0.62% 992,703 -5% 0.03% $35,861,396
PRICE T ROWE ASSOCIATES INC /MD/ 0.6% 958,471 -38% 0% $34,621,000
EVENTIDE ASSET MANAGEMENT, LLC 0.6% 954,531 0% 0.57% $34,482,432
TWO SIGMA INVESTMENTS, LP 0.56% 889,870 +45% 0.05% $32,146,554
Bank of New York Mellon Corp 0.55% 872,551 -3.7% 0.01% $31,520,899
PRINCIPAL FINANCIAL GROUP INC 0.49% 784,172 -1.6% 0.01% $28,328,214
CITIGROUP INC 0.47% 746,919 +8.9% 0.02% $26,982,449
FMR LLC 0.45% 711,343 -54% 0% $25,697,258
Nuveen, LLC 0.45% 710,772 +8.2% 0.01% $25,676,639
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.45% 708,331 -41% 0.04% $25,588,457

Institutional Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 34,552 $1,031,751 -$20,523 $29.81 5
2025 Q3 99,009,650 $3,576,821,678 -$107,526,423 $36.12 349
2025 Q2 101,638,266 $3,648,002,900 +$109,857,272 $35.99 353
2025 Q1 98,398,150 $3,879,789,142 +$91,891,680 $39.43 369
2024 Q4 96,830,910 $2,914,307,732 -$70,120,285 $30.10 324
2024 Q3 100,936,245 $2,361,533,461 -$22,928,710 $23.39 301
2024 Q2 93,106,342 $1,656,377,242 +$72,098,870 $17.79 250
2024 Q1 89,395,436 $1,359,715,515 -$24,629,865 $15.21 236
2023 Q4 54,988 $939,195 -$6,923,865 $17.08 1
2023 Q3 89,551,733 $748,415,364 -$269,081,437 $8.36 228
2023 Q2 87,325,953 $2,169,193,409 -$102,701,397 $24.84 239
2023 Q1 93,835,669 $1,411,260,456 +$45,654,165 $15.04 204
2022 Q4 93,300,764 $1,103,747,356 -$28,438,335 $11.83 193
2022 Q3 97,609,934 $577,826,362 -$20,693,675 $5.92 164
2022 Q2 88,801,039 $376,910,208 +$45,365,925 $4.25 155
2022 Q1 99,678,498 $948,067,130 -$98,444,664 $9.51 166
2021 Q4 99,676,103 $1,892,496,658 +$31,189,610 $19.00 181
2021 Q3 96,315,754 $3,203,847,013 -$41,674,730 $33.28 214
2021 Q2 95,533,232 $3,705,614,631 -$96,817,570 $38.79 228
2021 Q1 98,803,943 $4,764,893,153 -$16,868,325 $48.20 233
2020 Q4 98,423,648 $5,120,086,671 +$667,853,144 $52.02 245
2020 Q3 86,354,689 $2,309,824,172 +$116,762,937 $26.76 179
2020 Q2 81,080,101 $1,578,018,112 +$377,219,461 $19.48 167
2020 Q1 63,805,332 $627,899,081 +$63,306,390 $9.84 140
2019 Q4 58,195,527 $645,917,548 +$107,759,200 $11.10 131
2019 Q3 48,119,038 $270,188,414 -$15,505,144 $5.62 106
2019 Q2 50,242,483 $434,393,474 +$22,593,202 $8.65 113
2019 Q1 47,978,588 $385,712,816 +$33,986,153 $8.04 105
2018 Q4 48,160,234 $197,447,948 -$2,134,863 $4.10 106
2018 Q3 47,655,094 $266,869,201 +$32,234,671 $5.60 120
2018 Q2 40,478,946 $532,322,958 +$24,272,286 $13.15 120
2018 Q1 38,594,906 $548,039,564 +$48,787,910 $14.20 118
2017 Q4 35,771,273 $293,328,387 -$8,671,207 $8.20 101
2017 Q3 35,611,280 $421,976,033 +$16,116,012 $11.85 95
2017 Q2 34,343,628 $345,171,615 +$34,167,511 $10.05 102
2017 Q1 30,791,059 $358,704,155 +$141,470,400 $11.65 93
2016 Q4 21,689,924 $100,856,746 -$33,378,279 $4.65 84
2016 Q3 26,933,456 $208,465,474 -$5,609,931 $7.74 68
2016 Q2 27,901,863 $169,085,192 -$14,604,990 $6.06 82
2016 Q1 29,568,032 $251,891,278 +$21,732,054 $8.52 77
2015 Q4 26,880,396 $320,683,141 -$6,209,665 $11.93 85
2015 Q3 24,908,226 $251,065,154 +$34,147,225 $10.08 80
2015 Q2 23,509,834 $390,081,213 +$18,789,504 $16.59 87
2015 Q1 18,317,880 $283,514,565 +$45,704,748 $15.48 77
2014 Q4 15,310,043 $242,316,998 +$26,297,826 $15.84 75
2014 Q3 15,453,539 $164,890,645 +$5,223,757 $10.67 64
2014 Q2 12,960,577 $121,699,408 +$12,442,519 $9.39 64
2014 Q1 11,640,376 $80,287,912 +$31,814,701 $6.90 48